Press Release

Collection Sites Signs Agreement with Premium Retailer Tanger Outlets and Successfully Lists Sites on Government of California COVID-19 Website

Toronto, Ontario December 18, 2020 — QuestCap Inc. (“QuestCap”) (NEO:QSC; OTC:COPRF; FRA:34C1) is pleased to announce the launch of an agreement between its wholly owned subsidiary, Collection Sites, LLC and Tanger Factory Outlet Centers, Inc. (NYSE: SKT) (“Tanger Outlets”), a leading operator and owner of open-air upscale outlet shopping centers. Further, the Government of California has approved Collection Sites listing of testing center locations, through it’s CLIA certified lab partner Alcala Labs, on the State’s COVID-19 website detailing the location of COVID-19 testing centres. This significant development is expected to help improve awareness of the individual sites and drive increased number of customers to each collection site in the state of Califorinia.

About the Tanger Outlets Agreement

Collection Sites will lease 50 x 100 ft of space in the parking lots of 33 shopping centers owned or managed by Tanger Outlets, for an initial 6-month term with the option to extend, expanding its extensive network of COVID-19 testing centres.

“We are excited to see Collection Sites continue to expand its footprint, now with over 700 contracted locations secured across the United States” says Mr. Doug Sommerville, CEO of QuestCap, Inc. “Each site offers a comprehensive COVID-19 testing solution, including insurance covered antigen, PCR, and antibody tests. By helping provide greater access to testing and making testing part of a regular shopping routine, we can help society flatten the curve.”

With this agreement, a network of ‘pop-up’ COVID-19 testing sites will be rolled out across the United States. The pop-up labs will be managed by Las Vegas based company Collection Sites, LLC and powered by Alcala Testing and Analysis Services, a CLIA-licensed  laboratory based in San Diego, California. Appointments and payments will be handled through an online portal

The network of pop-up labs’ will be located across 33 Tanger Outlet locations in 19 U.S. states, with Texas and Arizona targeted initially. Testing sites will now be available for Americans seeking fast, available, and accurate testing for themselves and their loved ones in the weeks and months ahead. The first location is set to begin installation in December 2020 with daily testing capacity of 150 tests per site and charging USD $59 to $139 per test.

QuestCap’s/Collection Sites’ real estate broker, Ryan Zickler of Zickler Associates LLC, also headquartered in Indiana, presented the concept to Tanger Outlets as a means to provide retail shoppers a convenient location for COVID testing throughout the U.S. at Tanger Outlets properties.  Zickler brokered the transaction and helped facilitate post lease execution logistics between the parties.

The key to flattening the curve is to increase testing.

The new testing centers will offer convenient access to rapid antibody and antigen (pending availability) tests – which take 8-10 minutes to administer and provide results within 24 hours. The sites also offer regular RT-PCR, with results within 24 hours of testing.  All tests can be administered with insurance coverage options. The tests results can be communicated via text or email and can be accompanied with a certificate of good health via a HIPAA-compliant smartphone application.

For more information about the pop-up lab, the available sites and services visit

About Tanger Outlets

Tanger Factory Outlet Centers, Inc. (NYSE: SKT) is a leading operator of open-air upscale outlet shopping centers that owns, or has an ownership interest in, a portfolio of 38 centers.  Tanger’s operating properties are located in 20 states and in Canada, totaling approximately 14.1 million square feet, leased to over 2,700 stores operated by more than 500 different brand name companies. The Company has more than 39 years of experience in the outlet industry and is a publicly-traded REIT. For more information on Tanger Outlet Centers, call 1-800-4TANGER or visit the Company’s website at

About QuestCap Inc.

QuestCap Inc. (NEO:QSC; OTC:COPRF; FRA:34C1)  seeks out disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate remarkable risk-adjusted returns for investors. Specifically, QuestCap offers investors a diversified investment in the COVID-19 medical space across three areas; prevention, detection, and treatment.

QuestCap has a team of renowned global medical and business advisors that have developed a proprietary business strategy to capitalize on high-margin opportunities in the COVID-19 space.  This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopaedic treatment, foot and ankle care, and sports medicine.

QuestCap’s primary focus is the sale of COVID-19 IgG/IgM antibody tests authorized by FDA under an EUA for use by authorized laboratories. This is achieved largely through two acquisitions: 100% of Collection Sites, LLC and 28% of Colombian Sanaty IPS. Collection sites is setting up a series of COVID-19 testing sites across the United States with appointments and payments will be handled through the online portal Sanaty is setting up a series of full-service medical clinics offering a complete COVID-19 testing solution.

For additional information, please contact:
Doug Sommerville, CEO
+1 416-301-5418

For investing inquiries please contact:
Evan Veryard

For US media enquires please contact:
Veronica Welch

Cautionary Note Regarding Forward-looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the agreement among Collection Sites LLC and Tanger Outlets; the proposed roll-out of testing sites; projected timelines for testing results; projected revenues from the testing; the pursuit by QuestCap of investment opportunities; and the merits or potential returns of any such investments. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.